Analyst Thomas Smith of Leerink Partners reiterated a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report), retaining the price target of $73.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Thomas Smith has given his Buy rating due to a combination of factors surrounding MoonLake Immunotherapeutics’ strategic developments and promising clinical programs. The company has reported its first-quarter financial results for 2025, confirming that its lead asset, sonelokimab, is on track for significant progress in treating various immuno-inflammatory diseases. The anticipated topline data from the Phase 3 VELA program, expected in September 2025, is crucial as it could demonstrate sonelokimab’s clinical differentiation from competitors, potentially leading to a competitive edge in the market.
Furthermore, MoonLake’s comprehensive development strategy includes several ongoing and upcoming trials, such as the VELA-TEEN program and the Phase 3 IZAR program, which are expected to yield results in the coming years. The company’s strong execution in its clinical trials, coupled with the potential for sonelokimab to show superior efficacy and safety, supports the optimistic outlook. These factors collectively contribute to the Buy rating, as they indicate potential for significant advancements and strategic interest in MoonLake’s offerings.
According to TipRanks, Smith is a top 100 analyst with an average return of 33.1% and a 45.98% success rate. Smith covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cartesian Therapeutics, and Immunovant.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $66.00 price target.